10-Q
Q1--12-310001850079false0001850079us-gaap:RevolvingCreditFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2023-03-310001850079tbio:ContingentPutOptionMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079tbio:PfizerMembertbio:ClinicalMember2023-03-310001850079us-gaap:AdditionalPaidInCapitalMember2022-03-310001850079us-gaap:MeasurementInputDefaultRateMember2022-12-310001850079us-gaap:LicenseMembertbio:PfizerMember2021-12-310001850079srt:MinimumMember2023-03-310001850079srt:MinimumMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-092022-08-090001850079us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:RestrictedStockUnitsRSUMember2022-12-310001850079us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001850079us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079tbio:EtonMemberus-gaap:NoncompeteAgreementsMember2021-11-182021-11-180001850079us-gaap:FurnitureAndFixturesMember2022-12-310001850079us-gaap:EmployeeStockMember2022-01-012022-03-310001850079tbio:EtonMemberus-gaap:TradeNamesMember2021-11-182021-11-180001850079us-gaap:LeaseholdImprovementsMember2023-03-310001850079us-gaap:LicenseMember2023-01-012023-03-310001850079tbio:ContingentPutOptionMember2023-03-310001850079tbio:RoyaltiesAndOtherRevenueMember2023-01-012023-03-310001850079us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembertbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-092022-08-090001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001850079tbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-092022-08-090001850079tbio:ContingentPutOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079tbio:SalesMilestonesMembersrt:MinimumMembertbio:PfizerMember2021-12-310001850079tbio:ContingentPutOptionMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:RetainedEarningsMember2023-03-310001850079us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:RetainedEarningsMember2023-01-012023-03-310001850079srt:MinimumMembertbio:PfizerMembertbio:ClinicalMember2021-12-310001850079us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001850079us-gaap:RetainedEarningsMember2022-03-310001850079tbio:ContingentPutOptionMember2022-01-012022-03-3100018500792023-01-012023-03-310001850079us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:CommonStockMember2022-12-310001850079us-gaap:ServiceMember2023-01-012023-03-3100018500792022-01-012022-03-310001850079us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079tbio:SecuredTermLoanFacilityMembertbio:PrepaymentsMadeDuringYearOneMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-090001850079tbio:A2021StockIncentivePlanMember2021-06-012021-06-300001850079us-gaap:CustomerRelationshipsMembertbio:EtonMember2021-11-182021-11-180001850079us-gaap:IPOMember2021-06-012021-06-300001850079us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100018500792022-03-310001850079us-gaap:ProductMember2022-01-012022-03-310001850079tbio:A2021StockIncentivePlanMember2021-06-300001850079us-gaap:EmployeeStockMember2023-01-012023-03-310001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:EmployeeStockMember2021-06-180001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:BuildingMember2021-09-300001850079tbio:RoyaltiesAndOtherRevenueMember2022-01-012022-03-310001850079us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001850079tbio:ContingentPutOptionMember2023-01-012023-03-310001850079us-gaap:BuildingMember2021-09-012021-09-300001850079us-gaap:RetainedEarningsMember2022-01-012022-03-310001850079us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001850079us-gaap:RevolvingCreditFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-090001850079us-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:ConstructionInProgressMember2023-03-310001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:CommonStockMember2021-12-310001850079us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001850079us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001850079us-gaap:ConstructionInProgressMember2022-12-310001850079us-gaap:RevolvingCreditFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-092022-08-090001850079us-gaap:IPOMember2021-06-182021-06-180001850079us-gaap:NoncompeteAgreementsMember2023-03-310001850079srt:MaximumMembertbio:TrancheTwoTermLoanMembertbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-090001850079us-gaap:RetainedEarningsMember2021-12-310001850079us-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:MeasurementInputDefaultRateMember2023-03-310001850079tbio:ContingentPutOptionMember2021-12-310001850079us-gaap:AdditionalPaidInCapitalMember2023-03-310001850079tbio:ResearchCollaborationMembertbio:PfizerMember2022-10-012022-12-310001850079us-gaap:IntellectualPropertyMember2023-03-310001850079us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001850079us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079tbio:PfizerMembertbio:MaterialRightsMember2023-01-012023-03-310001850079srt:MaximumMembertbio:ShortTermLeaseMember2023-03-310001850079tbio:ContingentPutOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:CommonStockMember2023-01-012023-03-310001850079us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-3100018500792019-03-0800018500792022-12-310001850079us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079tbio:EtonMember2021-11-182021-11-180001850079us-gaap:TradeNamesMember2022-12-310001850079us-gaap:FairValueInputsLevel2Membertbio:ContingentPutOptionMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:ProductMember2023-01-012023-03-310001850079us-gaap:TradeNamesMember2023-03-310001850079us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:EmployeeStockMember2023-01-012023-03-310001850079us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:CommercialPaperMember2023-03-310001850079us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001850079us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079tbio:TrancheThreeTermLoanMembersrt:MaximumMembertbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-090001850079tbio:PrepaymentsMadeDuringYearTwoMembertbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-090001850079tbio:A2021StockIncentivePlanMember2023-03-310001850079tbio:ResearchCollaborationMembertbio:PfizerMember2023-04-012021-12-310001850079us-gaap:EmployeeStockMember2023-03-310001850079tbio:ComputerHardwareAndSoftwareMember2022-12-310001850079us-gaap:CommonStockMember2022-03-310001850079us-gaap:IntellectualPropertyMember2022-12-310001850079us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001850079us-gaap:FairValueInputsLevel2Membertbio:ContingentPutOptionMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:RetainedEarningsMember2022-12-310001850079us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:EmployeeStockMember2021-06-182021-06-180001850079tbio:ContingentPutOptionMember2022-03-3100018500792023-04-300001850079us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001850079us-gaap:TechnologyBasedIntangibleAssetsMember2021-11-182021-11-180001850079us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001850079tbio:PrepaymentsMadeDuringYearThreeMembertbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-090001850079us-gaap:NoncompeteAgreementsMember2022-12-310001850079srt:MaximumMember2023-03-310001850079us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001850079us-gaap:OverAllotmentOptionMember2021-06-182021-06-180001850079tbio:SalesMilestonesMembersrt:MaximumMembertbio:PfizerMember2021-12-310001850079tbio:ContingentPutOptionMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:SellingAndMarketingExpenseMember2023-01-012023-03-310001850079tbio:PfizerMember2023-03-310001850079us-gaap:MachineryAndEquipmentMember2023-03-310001850079us-gaap:MeasurementInputCostToSellMember2022-12-3100018500792022-01-012022-12-310001850079us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001850079us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:BuildingMember2023-03-310001850079us-gaap:CustomerRelationshipsMember2022-12-310001850079us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:LeaseholdImprovementsMember2022-12-310001850079us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001850079tbio:TrancheOneTermLoanMembersrt:MaximumMembertbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-090001850079us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMembertbio:LoanAgreement2021Member2023-03-310001850079us-gaap:RestrictedStockUnitsRSUMember2023-03-310001850079tbio:ComputerHardwareAndSoftwareMember2023-03-310001850079us-gaap:MeasurementInputCostToSellMember2023-03-310001850079tbio:A2021EquityIncentivePlanMember2021-03-030001850079us-gaap:CustomerRelationshipsMember2023-03-310001850079us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079srt:MaximumMembertbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-090001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-3100018500792023-03-310001850079us-gaap:MachineryAndEquipmentMember2022-12-310001850079us-gaap:AdditionalPaidInCapitalMember2021-12-310001850079tbio:CreditSecurityAndGuarantyAgreementMembertbio:LoanAgreementsMember2022-08-092022-08-090001850079tbio:CollaborationRevenueMember2022-01-012022-03-310001850079srt:MaximumMembertbio:A2021StockIncentivePlanMember2021-06-300001850079tbio:A2019StockPlanMember2019-03-310001850079us-gaap:ServiceMember2022-01-012022-03-310001850079us-gaap:AdditionalPaidInCapitalMember2022-12-310001850079tbio:CollaborationRevenueMember2023-01-012023-03-3100018500792021-12-310001850079us-gaap:CommonStockMember2023-03-310001850079tbio:ContingentPutOptionMember2022-12-310001850079us-gaap:CommonStockMember2022-01-012022-03-310001850079us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembertbio:SecuredTermLoanFacilityMembertbio:CreditSecurityAndGuarantyAgreementMember2022-08-090001850079srt:MaximumMembertbio:PfizerMembertbio:ClinicalMember2021-12-310001850079us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:CommercialPaperMember2022-12-310001850079tbio:EtonMember2021-11-180001850079us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310001850079us-gaap:FurnitureAndFixturesMember2023-03-310001850079tbio:ContingentPutOptionMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001850079us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001850079us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31xbrli:purexbrli:sharesiso4217:USDxbrli:sharestbio:Leaseiso4217:USD
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to _____________

Commission file number 001-40497

Telesis Bio Inc.

(Exact name of registrant as specified in its charter)

Delaware

45-1216839

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

10431 Wateridge Circle, Suite 150, San Diego, CA

92121

(Address of Principal Executive Offices)

(Zip Code)

(858) 228-4115

Registrant's telephone number, including area code

 

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

TBIO

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No

The registrant had outstanding 29,698,496 shares of common stock as of April 30, 2023.

 

 

 


Table of Contents

 

Table of Contents

 

Page

Part I - Financial Information

 

Item 1. Financial Statements (Unaudited)

5

Condensed Consolidated Balance Sheets

5

Condensed Consolidated Statements of Operations and Comprehensive Loss

6

Condensed Consolidated Statements of Stockholders' Equity

7

Condensed Consolidated Statements of Cash Flows

8

Notes to Condensed Consolidated Financial Statements

9

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3. Quantitative and Qualitative Disclosures About Market Risk

37

Item 4. Controls and Procedures

37

Part II - Other Information

 

Item 1. Legal Proceedings

39

Item 1A. Risk Factors

39

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

73

Item 3. Defaults Upon Senior Securities

74

Item 4. Mine Safety Disclosures

74

Item 5. Other Information

74

Item 6. Exhibits

75

Signatures

76

 

2


Table of Contents

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (Quarterly Report) contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal” “intend,” “may,” “objective” “plan,” “predict,” “potential,” “project,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:

estimates of the synthetic biology market, market growth, and new market expansion;
our future revenue, expenses, capital requirements and our needs for additional financing;
our expectations regarding the rate and degree of market acceptance of our BioXp systems, BioXp kits and benchtop reagents;
the ability of our products to facilitate the design-build-test paradigm of synthetic biology;
the size and growth of the synthetic biology market and competitive companies and technologies and our industry;
our ability to manage and grow our business;
our ability to develop and commercialize new products; our ability to establish and maintain intellectual property protection for our products or avoid or defend claims of infringement;
the performance of third-party manufacturers and suppliers and our ability to qualify second-source suppliers;
the potential effects of government regulation;
our ability to hire and retain key personnel and to manage our future growth effectively;
our ability to obtain additional financing in future offerings;
the volatility of the trading price of our common stock;
the impact of local, regional, and national and international economic conditions and events, including the war between Russia and Ukraine;
our expectations about market trends;
our anticipated use of our existing resources; and
other risks and uncertainties, including those listed in the section titled “Risk Factors.”

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this Quarterly Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not

3


Table of Contents

 

be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we undertake no obligation to update or revise any forward-looking statements contained herein to reflect events or circumstances after the date of this Quarterly Report, whether as a result of any new information, future events or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

4


Table of Contents

 

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Telesis Bio Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(Unaudited)

 

March 31,
2023

 

 

December 31,
2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

23,357

 

 

$

30,419

 

Restricted cash

 

 

175

 

 

 

175

 

Short-term investments

 

 

8,710

 

 

 

13,159

 

Accounts receivable, net of allowance for bad debts of $343 at
   March 31, 2023 and December 31, 2022

 

 

5,835

 

 

 

5,851

 

Inventory

 

 

2,294

 

 

 

2,200

 

Prepaid expenses and other current assets

 

 

2,568

 

 

 

3,288

 

Total current assets

 

 

42,939

 

 

 

55,092

 

Property and equipment, net

 

 

7,256

 

 

 

6,861

 

Right-of-use assets

 

 

21,346

 

 

 

1,660

 

Other long-term assets

 

 

981

 

 

 

981

 

Goodwill

 

 

14,886

 

 

 

14,886

 

Other intangible assets, net

 

 

1,754

 

 

 

1,882

 

Total assets

 

$

89,162

 

 

$

81,362

 

Liabilities and stockholders' equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,439

 

 

$

1,295

 

Accrued employee expenses

 

 

3,297

 

 

 

5,858

 

Finance lease liability, current portion

 

 

27

 

 

 

59

 

Operating lease liability, current portion

 

 

747

 

 

 

578

 

Deferred revenue, current portion

 

 

2,975

 

 

 

3,958

 

Other accrued liabilities

 

 

1,321

 

 

 

1,377

 

Other current liabilities

 

 

434

 

 

 

373

 

Total current liabilities

 

 

11,240

 

 

 

13,498

 

Finance lease liability, net of current portion

 

 

30

 

 

 

30

 

Operating lease liability, net of current portion

 

 

21,157

 

 

 

1,111

 

Notes payable, net of discount and current portion

 

 

19,755

 

 

 

19,649

 

Derivative liabilities

 

 

227

 

 

 

367

 

Deferred revenue, net of current portion

 

 

134

 

 

 

142

 

Total liabilities

 

$

52,543

 

 

$

34,797

 

Commitments and contingencies (Note 12)

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

Preferred stock, $.0001 par value; 5,000,000 shares authorized at March 31, 2023 and December 31, 2022. No shares issued and outstanding

 

 

 

 

 

 

Common stock, $.0001 par value; 100,000,000 shares authorized at
   March 31, 2023 and December 31, 2022;
29,698,496 and 29,647,091 shares
   issued and outstanding at March 31, 2023 and December 31, 2022, respectively

 

 

5

 

 

 

5

 

Additional paid-in capital

 

 

161,472

 

 

 

160,304

 

Accumulated other comprehensive income (loss)

 

 

2

 

 

 

(3

)

Accumulated deficit

 

 

(124,860

)

 

 

(113,741

)

Total stockholders' equity

 

 

36,619

 

 

 

46,565

 

Total liabilities and stockholders' equity

 

$

89,162

 

 

$

81,362

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5


Table of Contents

 

Telesis Bio Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Revenue:

 

 

 

 

 

 

 

Product revenue

 

 

$

3,001

 

 

$

2,423

 

Service revenue

 

 

 

1,674

 

 

 

1,705

 

Collaboration revenue

 

 

 

962

 

 

 

962

 

Royalties and other revenue

 

 

 

679

 

 

 

546

 

Total revenue

 

 

 

6,316

 

 

 

5,636

 

Cost of revenue

 

 

 

2,805

 

 

 

2,858

 

Gross profit

 

 

 

3,511

 

 

 

2,778

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

 

 

5,121

 

 

 

6,305

 

Sales and marketing

 

 

 

3,807

 

 

 

3,546

 

General and administrative

 

 

 

5,554

 

 

 

5,790

 

Total operating expenses

 

 

 

14,482

 

 

 

15,641

 

Loss from operations

 

 

 

(10,971

)

 

 

(12,863

)

Other expense, net:

 

 

 

 

 

 

 

Interest expense, net

 

 

 

(249

)

 

 

(336

)

Change in fair value of derivative liabilities

 

 

 

140

 

 

 

23

 

Other expense, net

 

 

 

(36

)

 

 

(12

)

Total other expense, net

 

 

 

(145

)

 

 

(325

)

Loss before provision for income taxes

 

 

 

(11,116

)

 

 

(13,188

)

Provision for income taxes

 

 

 

(3

)

 

 

(6

)

Net loss

 

 

$

(11,119

)

 

$

(13,194

)

 

 

 

 

 

 

 

 

Other comprehensive loss:

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale short-term investments

 

 

 

5

 

 

 

(16

)

Total comprehensive loss

 

 

$

(11,114

)

 

$

(13,210

)

Net loss attributable to common stockholders

 

 

$

(11,119

)

 

$

(13,194

)

Net loss per share attributable to common stockholders—basic and diluted

 

 

$

(0.37

)

 

$

(0.45

)

Weighted average common stock outstanding—basic and diluted

 

 

 

29,663,006

 

 

 

29,331,325

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6


Table of Contents

 

Telesis Bio Inc.

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

(Unaudited)

 

 

Common Stock

 

 

Additional
Paid-in
Capital

 

 

Accumulated
Deficit

 

 

Accumulated Other Comprehensive Income (Loss)

 

 

Total
Stockholders'
Equity (Deficit)

 

 

Shares

 

 

Amount

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at December 31, 2021

 

 

29,318,578

 

 

$

5

 

 

$

156,049

 

 

$

(65,270

)

 

$

 

 

$

90,784

 

Issuance of Common Stock upon exercise of stock options

 

 

70,534

 

 

 

 

 

 

78

 

 

 

 

 

 

 

 

 

78

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

448

 

 

 

 

 

 

 

 

 

448

 

Unrealized loss on available-for-sale short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(16

)

 

 

(16

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(13,194

)

 

 

 

 

 

(13,194

)

Balances at March 31, 2022

 

 

29,389,112

 

 

$

5

 

 

$

156,575

 

 

$

(78,464

)

 

$

(16

)

 

$

78,100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at December 31, 2022

 

 

29,647,091

 

 

$

5

 

 

$

160,304

 

 

$

(113,741

)

 

$

(3

)

 

$

46,565

 

Issuance of Common Stock upon exercise of stock options

 

 

17,380

 

 

 

 

 

 

12

 

 

 

 

 

 

 

 

 

12

 

Vesting of restricted stock units

 

 

34,025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,156

 

 

 

 

 

 

 

 

 

1,156

 

Unrealized gain on available-for-sale short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5

 

 

 

5

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(11,119

)

 

 

 

 

 

(11,119

)

Balances at March 31, 2023

 

 

29,698,496

 

 

$

5

 

 

$

161,472

 

 

$

(124,860

)

 

$

2

 

 

$

36,619

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

7


Table of Contents

 

Telesis Bio Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

 

Three Months Ended March 31,

 

 

2023

 

 

2022

 

Cash Flows From Operating Activities:

 

 

 

 

 

 

Net loss

 

$

(11,119

)

 

$

(13,194

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation

 

 

386

 

 

 

217

 

Amortization of intangible assets

 

 

128

 

 

 

113

 

Amortization of debt discount

 

 

97

 

 

 

95

 

Stock-based compensation

 

 

1,156

 

 

 

448

 

Amortization of operating lease right-of-use assets

 

 

625

 

 

 

263

 

Change in fair value of derivative liabilities

 

 

(140

)

 

 

(23

)

Non-cash interest on finance leases

 

 

 

 

 

(1

)

Loss on asset disposal

 

 

28

 

 

 

 

Accretion of discount on short-term investments

 

 

(139

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

16

 

 

 

(896

)

Inventories

 

 

(94

)

 

 

(168

)

Deposits, prepaid expenses and other current assets

 

 

720

 

 

 

284

 

Accounts payable, accrued payroll and accrued liabilities

 

 

(1,742

)

 

 

673

 

Deferred revenue

 

 

(991

)

 

 

6,915

 

Operating lease liabilities

 

 

(98

)

 

 

(348

)

Net cash used in operating activities

 

 

(11,167

)

 

 

(5,622

)

Cash Flows From Investing Activities:

 

 

 

 

 

 

Proceeds from maturities of short-term investments

 

 

11,750

 

 

 

 

Purchase of property and equipment

 

 

(470

)

 

 

(459

)

Purchases of short-term investments

 

 

(7,157

)

 

 

(45,424

)

Net cash provided by (used in) investing activities

 

 

4,123

 

 

 

(45,883

)

Cash Flows From Financing Activities:

 

 

 

 

 

 

Payments on finance leases

 

 

(30

)

 

 

(20

)

Proceeds from the exercise of common stock options

 

 

12

 

 

 

78

 

Net cash (used in) provided by financing activities

 

 

(18

)

 

 

58

 

Net (Decrease) Increase In Cash, Cash Equivalents, and Restricted Cash

 

 

(7,062

)

 

 

(51,447

)

Cash, cash equivalents, and restricted cash at beginning of period

 

 

30,594

 

 

 

82,806

 

Cash, cash equivalents, and restricted cash at end of period

 

$

23,532

 

 

$

31,359

 

 

 

 

 

 

 

 

Supplemental Disclosure Of Cash Flow Information:

 

 

 

 

 

 

Cash paid for interest

 

$

509

 

 

$

273

 

Purchases of property and equipment included in accounts payable and accrued expenses

 

$

487

 

 

$

269

 

Right-of-use-assets obtained in exchange for operating lease liabilities

 

$

20,313

 

 

$

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

8


Table of Contents

 

Telesis Bio Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1.
ORGANIZATION AND OPERATIONS

Business

Telesis Bio Inc. (the Company) was incorporated in the state of Delaware in March 2011, as Synthetic Genomics Solution, Inc., a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI). The Company changed its name to SGI-DNA, Inc. (SGI-DNA) in February 2013, and to Codex DNA, Inc. in March 2020, and then to Telesis Bio Inc. in November 2022. SGI-DNA Limited, a United Kingdom company focused on sales and marketing activities, is a wholly owned subsidiary of Telesis Bio Inc. The Company manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.

On November 18, 2021, the Company entered into a Share Purchase Agreement, with the stockholders of EtonBio, Inc., a California corporation (Eton), pursuant to which the Company agreed to purchase all of the outstanding shares of capital stock of Eton (see Note 7). The total purchase price was approximately $14.1 million, which was funded with the Company’s existing cash on hand. Eton is a San Diego-based biotech company specializing in synthetic biology products and services, including DNA sequencing and oligo synthesis, for the global academic research, pharmaceutical, and biotechnology industries. Eton also markets DNA prep services and products such as antibodies, peptides, and metabolism assay kits.

Since its inception, the Company has devoted substantially all of its efforts to raising capital, commercializing its current products, and developing new product offerings. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of products. Principal among these risks are a dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and manufacturing of its products. The Company’s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, commercialize its products, generate revenue, meet its obligations, and, ultimately, become profitable.

Products currently under development will require significant additional research and development efforts. These efforts require significant amounts of additional capital, adequate personnel and infrastructure.

Since inception, the Company has incurred cumulative operating losses and negative cash flows from operations. These operating losses and negative cash flows have been financed principally from the issuance of equity securities and debt. The Company’s ability to continue as a going concern is dependent upon the ability to raise additional debt or equity capital. There can be no assurance that such capital will be available in sufficient amounts, on terms acceptable to the Company, or at all. Risks to which the Company is exposed include uncertainties related to the ability to achieve revenue-generating products; current and potential competitors with greater financial, technological, production, and marketing resources; dependence on key management personnel; and raising additional capital, as needed. Based upon the Company’s current plans, management believes that the financial resources available as of the date of this report are insufficient to fund the Company’s operations for the next twelve months following the issuance date of these condensed consolidated financial statements. The Company will seek additional financing opportunities in the coming months to increase the financial resources available to the Company.

Going Concern

Under Accounting Standards Update (ASU”) No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. The Company has incurred losses and negative cash flows from operations in each year since its inception. As of March 31, 2023, the Company had an accumulated deficit of $124.9 million. In June 2021, the Company received $112.5 million in net proceeds upon completion of its IPO. The Company has also received $8.0 million in upfront payments and $2.5 million in milestone payments

9


Table of Contents

 

under its collaboration with Pfizer Inc. (Note 15). Until such time, if ever, as the Company can generate substantial product revenue and/or collaboration revenue and achieve sustained profitability, the Company expects to finance its cash needs through a combination of equity offerings, drawing on existing credit facilities, collaborations, strategic alliances, licensing arrangements and other sources of funding. However, the existing credit facilities may not be available if certain financial covenants are not achieved. Although the Company is actively pursuing new financing opportunities, it may not be able to raise cash on terms acceptable to the Company or at all. There can be no assurance that the Company will be successful in obtaining additional funding. Financings, if available, may be on terms that are dilutive to shareholders, and the prices at which new investors would be willing to purchase the Company’s securities may be lower than the current price of its common stock. The holders of new securities may also receive rights, preferences or privileges that are senior to those of existing holders of common stock. If additional financing is not available or is not available on acceptable terms, the Company could be forced to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products that the Company would otherwise prefer to develop and market itself. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Based upon the Company’s current level of expenditures, management believes there currently are insufficient financial resources to fund the Company’s operations for at least twelve months from the filing date of this Quarterly Report. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP), and include the accounts of the Company and its wholly owned subsidiaries after the elimination of all significant intercompany accounts and transactions. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and as amended by Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2023 and 2022 and the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 22, 2023, as amended on May 1, 2023 (the Annual Report). The condensed consolidated balance sheet data as of December 31, 2022 presented for comparative purposes was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by U.S. GAAP and Article 8 of Regulation S-X. The results for the three months ended March 31, 2023 and 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods, or any future year or period.

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2022 included in the Annual Report. Since the date of the audited consolidated financial statements for the year ended

10


Table of Contents

 

December 31, 2022 included in the Annual Report, there have been no changes to its significant accounting policies except as noted below.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods presented. Key estimates in the consolidated financial statements include the Company’s ability to continue as a going concern, revenue recognition, impairment assessment for goodwill and intangible assets, allowance for doubtful accounts, estimated useful lives of property and equipment, valuation of inventory, accrued expenses, valuation of deferred income tax assets, valuation of derivative liabilities, share-based compensation, and accrued warranty are subject to significant estimation. Actual results could differ from those estimates.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current presentation. The Company reclassified an aggregate of $0.1 million of field services and technical support costs from the research and development line to the sales and marketing and general administrative lines on the consolidated statement of operations and comprehensive loss for the three months ended March 31, 2022. The Company believes these costs are better reflected in sales and marketing. The reclassification had no impact on net loss for the three months ended March 31, 2022.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) (ASU 2016-13). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. This update is effective for entities other than public business entities, including emerging growth companies that elected to defer compliance with new or revised financial accounting standards until a company that is not an issuer is required to comply with such standards, for annual reporting periods beginning after December 15, 2022. The Company adopted this standard on January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments improve comparability after the business combination by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. The ASU is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2022. Entities should apply the amendments prospectively and early adoption is permitted. The Company adopted this standard on January 1, 2023. The adoption of ASU 2021-08 did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.

11


Table of Contents

 

3.
FAIR VALUE MEASUREMENT

The following tables summarize the fair values of the Company’s assets and liabilities on the condensed consolidated balance sheets which comprise of money market funds, commercial paper, U.S. government agencies and the contingent put option liability (in thousands):

 

 

Fair value measurements as of March 31, 2023

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

21,371

 

 

$

 

 

$

 

 

$

21,371

 

Commercial paper

 

 

 

 

 

1,486

 

 

 

 

 

 

1,486

 

U.S. government agencies

 

 

 

 

 

7,224

 

 

 

 

 

 

7,224

 

Total

 

$

21,371

 

 

$

8,710

 

 

$

 

 

$

30,081

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Contingent put option liability

 

$

 

 

$

 

 

$

227

 

 

$

227

 

Total

 

$

 

 

$

 

 

$

227

 

 

$

227

 

 

 

Fair value measurements as of December 31, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets